Cargando…

Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits

OBJECTIVES: To determine the risk of mortality and need for aortic valve replacement (AVR) in patients with low-flow low-gradient (LFLG) aortic stenosis (AS). METHODS: A longitudinal multicentre study including consecutive patients with severe AS (aortic valve area [AVA] < 1.0 cm(2)) and normal l...

Descripción completa

Detalles Bibliográficos
Autores principales: Galian-Gay, Laura, Escalona Silva, Roxana Andreina, Teixidó-Turà, Gisela, Casas, Guillem, Ferrer-Sistach, Elena, Mitroi, Cristina, Mingo, Susana, Monivas, Vanessa, Saura, Daniel, Vidal, Bàrbara, Trasca, Livia, Moral, Sergio, Calvo, Francisco, Castiñeira Busto, Maria, Sánchez, Violeta, Gonzalez, Ariana, Guzman, Gabriela, Mora, Marta Noris, Arnau Vives, MiguelÁngel, Peteiro, Jesús, Bouzas, Alberto, Mas-Stachurska, Aleksandra, González-Alujas, Teresa, Gutiérrez, Laura, Fernandez-Galera, Rubén, Valente, Filipa, Guala, Andrea, Ruiz-Muñoz, Aroa, Avilés, Cesar Augusto Sao, Palomares, José F. Rodríguez, Ferreira, Ignacio, Evangelista, Artur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011160/
https://www.ncbi.nlm.nih.gov/pubmed/35433871
http://dx.doi.org/10.3389/fcvm.2022.852954
_version_ 1784687627707875328
author Galian-Gay, Laura
Escalona Silva, Roxana Andreina
Teixidó-Turà, Gisela
Casas, Guillem
Ferrer-Sistach, Elena
Mitroi, Cristina
Mingo, Susana
Monivas, Vanessa
Saura, Daniel
Vidal, Bàrbara
Trasca, Livia
Moral, Sergio
Calvo, Francisco
Castiñeira Busto, Maria
Sánchez, Violeta
Gonzalez, Ariana
Guzman, Gabriela
Mora, Marta Noris
Arnau Vives, MiguelÁngel
Peteiro, Jesús
Bouzas, Alberto
Mas-Stachurska, Aleksandra
González-Alujas, Teresa
Gutiérrez, Laura
Fernandez-Galera, Rubén
Valente, Filipa
Guala, Andrea
Ruiz-Muñoz, Aroa
Avilés, Cesar Augusto Sao
Palomares, José F. Rodríguez
Ferreira, Ignacio
Evangelista, Artur
author_facet Galian-Gay, Laura
Escalona Silva, Roxana Andreina
Teixidó-Turà, Gisela
Casas, Guillem
Ferrer-Sistach, Elena
Mitroi, Cristina
Mingo, Susana
Monivas, Vanessa
Saura, Daniel
Vidal, Bàrbara
Trasca, Livia
Moral, Sergio
Calvo, Francisco
Castiñeira Busto, Maria
Sánchez, Violeta
Gonzalez, Ariana
Guzman, Gabriela
Mora, Marta Noris
Arnau Vives, MiguelÁngel
Peteiro, Jesús
Bouzas, Alberto
Mas-Stachurska, Aleksandra
González-Alujas, Teresa
Gutiérrez, Laura
Fernandez-Galera, Rubén
Valente, Filipa
Guala, Andrea
Ruiz-Muñoz, Aroa
Avilés, Cesar Augusto Sao
Palomares, José F. Rodríguez
Ferreira, Ignacio
Evangelista, Artur
author_sort Galian-Gay, Laura
collection PubMed
description OBJECTIVES: To determine the risk of mortality and need for aortic valve replacement (AVR) in patients with low-flow low-gradient (LFLG) aortic stenosis (AS). METHODS: A longitudinal multicentre study including consecutive patients with severe AS (aortic valve area [AVA] < 1.0 cm(2)) and normal left ventricular ejection fraction (LVEF). Patients were classified as: high-gradient (HG, mean gradient ≥ 40 mmHg), normal-flow low-gradient (NFLG, mean gradient < 40 mmHg, indexed systolic volume (SVi) > 35 ml/m(2)) and LFLG (mean gradient < 40 mmHg, SVi ≤ 35 ml/m(2)). RESULTS: Of 1,391 patients, 147 (10.5%) had LFLG, 752 (54.1%) HG, and 492 (35.4%) NFLG. Echocardiographic parameters of the LFLG group showed similar AVA to the HG group but with less severity in the dimensionless index, calcification, and hypertrophy. The HG group required AVR earlier than NFLG (p < 0.001) and LFLG (p < 0.001), with no differences between LFLG and NFLG groups (p = 0.358). Overall mortality was 27.7% (CI 95% 25.3–30.1) with no differences among groups (p = 0.319). The impact of AVR in terms of overall mortality reduction was observed the most in patients with HG (hazard ratio [HR]: 0.17; 95% CI: 0.12–0.23; p < 0.001), followed by patients with LFLG (HR: 0.25; 95% CI: 0.13–0.49; p < 0.001), and finally patients with NFLG (HR: 0.29; 95% CI: 0.20–0.44; p < 0.001), with a risk reduction of 84, 75, and 71%, respectively. CONCLUSIONS: Paradoxical LFLG AS affects 10.5% of severe AS, and has a lower need for AVR than the HG group and similar to the NFLG group, with no differences in mortality. AVR had a lower impact on LFLG AS compared with HG AS. Therefore, the findings of the present study showed LFLG AS to have an intermediate clinical risk profile between the HG and NFHG groups.
format Online
Article
Text
id pubmed-9011160
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90111602022-04-16 Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits Galian-Gay, Laura Escalona Silva, Roxana Andreina Teixidó-Turà, Gisela Casas, Guillem Ferrer-Sistach, Elena Mitroi, Cristina Mingo, Susana Monivas, Vanessa Saura, Daniel Vidal, Bàrbara Trasca, Livia Moral, Sergio Calvo, Francisco Castiñeira Busto, Maria Sánchez, Violeta Gonzalez, Ariana Guzman, Gabriela Mora, Marta Noris Arnau Vives, MiguelÁngel Peteiro, Jesús Bouzas, Alberto Mas-Stachurska, Aleksandra González-Alujas, Teresa Gutiérrez, Laura Fernandez-Galera, Rubén Valente, Filipa Guala, Andrea Ruiz-Muñoz, Aroa Avilés, Cesar Augusto Sao Palomares, José F. Rodríguez Ferreira, Ignacio Evangelista, Artur Front Cardiovasc Med Cardiovascular Medicine OBJECTIVES: To determine the risk of mortality and need for aortic valve replacement (AVR) in patients with low-flow low-gradient (LFLG) aortic stenosis (AS). METHODS: A longitudinal multicentre study including consecutive patients with severe AS (aortic valve area [AVA] < 1.0 cm(2)) and normal left ventricular ejection fraction (LVEF). Patients were classified as: high-gradient (HG, mean gradient ≥ 40 mmHg), normal-flow low-gradient (NFLG, mean gradient < 40 mmHg, indexed systolic volume (SVi) > 35 ml/m(2)) and LFLG (mean gradient < 40 mmHg, SVi ≤ 35 ml/m(2)). RESULTS: Of 1,391 patients, 147 (10.5%) had LFLG, 752 (54.1%) HG, and 492 (35.4%) NFLG. Echocardiographic parameters of the LFLG group showed similar AVA to the HG group but with less severity in the dimensionless index, calcification, and hypertrophy. The HG group required AVR earlier than NFLG (p < 0.001) and LFLG (p < 0.001), with no differences between LFLG and NFLG groups (p = 0.358). Overall mortality was 27.7% (CI 95% 25.3–30.1) with no differences among groups (p = 0.319). The impact of AVR in terms of overall mortality reduction was observed the most in patients with HG (hazard ratio [HR]: 0.17; 95% CI: 0.12–0.23; p < 0.001), followed by patients with LFLG (HR: 0.25; 95% CI: 0.13–0.49; p < 0.001), and finally patients with NFLG (HR: 0.29; 95% CI: 0.20–0.44; p < 0.001), with a risk reduction of 84, 75, and 71%, respectively. CONCLUSIONS: Paradoxical LFLG AS affects 10.5% of severe AS, and has a lower need for AVR than the HG group and similar to the NFLG group, with no differences in mortality. AVR had a lower impact on LFLG AS compared with HG AS. Therefore, the findings of the present study showed LFLG AS to have an intermediate clinical risk profile between the HG and NFHG groups. Frontiers Media S.A. 2022-04-01 /pmc/articles/PMC9011160/ /pubmed/35433871 http://dx.doi.org/10.3389/fcvm.2022.852954 Text en Copyright © 2022 Galian-Gay, Escalona Silva, Teixidó-Turà, Casas, Ferrer-Sistach, Mitroi, Mingo, Monivas, Saura, Vidal, Trasca, Moral, Calvo, Castiñeira Busto, Sánchez, Gonzalez, Guzman, Mora, Arnau Vives, Peteiro, Bouzas, Mas-Stachurska, González-Alujas, Gutiérrez, Fernandez-Galera, Valente, Guala, Ruiz-Muñoz, Avilés, Palomares, Ferreira and Evangelista. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Galian-Gay, Laura
Escalona Silva, Roxana Andreina
Teixidó-Turà, Gisela
Casas, Guillem
Ferrer-Sistach, Elena
Mitroi, Cristina
Mingo, Susana
Monivas, Vanessa
Saura, Daniel
Vidal, Bàrbara
Trasca, Livia
Moral, Sergio
Calvo, Francisco
Castiñeira Busto, Maria
Sánchez, Violeta
Gonzalez, Ariana
Guzman, Gabriela
Mora, Marta Noris
Arnau Vives, MiguelÁngel
Peteiro, Jesús
Bouzas, Alberto
Mas-Stachurska, Aleksandra
González-Alujas, Teresa
Gutiérrez, Laura
Fernandez-Galera, Rubén
Valente, Filipa
Guala, Andrea
Ruiz-Muñoz, Aroa
Avilés, Cesar Augusto Sao
Palomares, José F. Rodríguez
Ferreira, Ignacio
Evangelista, Artur
Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits
title Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits
title_full Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits
title_fullStr Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits
title_full_unstemmed Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits
title_short Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits
title_sort prognosis of paradoxical low-flow low-gradient aortic stenosis: a severe, non-critical form, with surgical treatment benefits
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011160/
https://www.ncbi.nlm.nih.gov/pubmed/35433871
http://dx.doi.org/10.3389/fcvm.2022.852954
work_keys_str_mv AT galiangaylaura prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT escalonasilvaroxanaandreina prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT teixidoturagisela prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT casasguillem prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT ferrersistachelena prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT mitroicristina prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT mingosusana prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT monivasvanessa prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT sauradaniel prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT vidalbarbara prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT trascalivia prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT moralsergio prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT calvofrancisco prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT castineirabustomaria prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT sanchezvioleta prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT gonzalezariana prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT guzmangabriela prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT moramartanoris prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT arnauvivesmiguelangel prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT peteirojesus prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT bouzasalberto prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT masstachurskaaleksandra prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT gonzalezalujasteresa prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT gutierrezlaura prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT fernandezgaleraruben prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT valentefilipa prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT gualaandrea prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT ruizmunozaroa prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT avilescesaraugustosao prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT palomaresjosefrodriguez prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT ferreiraignacio prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits
AT evangelistaartur prognosisofparadoxicallowflowlowgradientaorticstenosisaseverenoncriticalformwithsurgicaltreatmentbenefits